Clinical Trials
49 trialsSelinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms
Zhongshan Hospital (Xiamen), Fudan University
FXS0683-001
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
University of Colorado, Denver
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
National Cancer Institute (NCI)
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
City of Hope Medical Center
PREeMPT
Medical College of Wisconsin
Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia
Jonsson Comprehensive Cancer Center
Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
M.D. Anderson Cancer Center
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
MYELO-CAN:ABX
University of Manitoba
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
University Health Network, Toronto
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nanfang Hospital, Southern Medical University
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
Eilean Therapeutics
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
University of Miami
ENERGIA
University of Turin, Italy
Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT
University of Arizona
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Shenzhen TargetRx Co., Ltd.
MDS
Thomas Jefferson University
GRACE
University of Manchester
IFN-α in Relapse Prevention.
Peking University People's Hospital
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
Peking Union Medical College Hospital
DETERMINE
Cancer Research UK
MPN-Exercise
Hannover Medical School
WELL-MPN
Brigham and Women's Hospital
ACTIVAQ
Hospices Civils de Lyon
Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
Peking University People's Hospital
TAGVEN
French Innovative Leukemia Organisation
Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis
Brigham and Women's Hospital
ROVER-01
Ryvu Therapeutics SA
DiP-in-CML
Gruppo Italiano Malattie EMatologiche dell'Adulto
PV
PharmaEssentia
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
BeBetter Med Inc
Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
AZA+Lus VS AZA Monotherapy in HR-MDS
Peking Union Medical College Hospital
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion
Assiut University
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TMLI-MA
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
TMLI-RI
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ACHIEVE2
TC Biopharm
MastCellHet
University Hospital, Toulouse
Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS
First Affiliated Hospital of Zhejiang University
MOZART
University Hospital, Angers
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Jiangsu Hansoh Pharmaceutical Co., Ltd.
BUSEQ
Institut Paoli-Calmettes